Roche
罗氏
Roche is a Swiss healthcare conglomerate whose 2005 launch of the 454 high-throughput sequencing platform helped crack open the genomics era, even if the technology was soon eclipsed by Illumina's Solexa system . Its pharmaceutical arm includes Japan's Chugai, from which Eli Lilly acquired a GLP-1 project for $50 million upfront five years before the obesity-drug boom . In China, Roche has built local R&D presence: Hong Shen led its Shanghai Innovation Center as of 2020 . The company has also partnered with computational drug-discovery firms such as XtalPi .
Related coverage: Roche appears in FreeS Fund portfolio tracking and consumer-sector pieces, but only as a passing name .
AI-generated — may contain errors, please verify.
Coverage
Yixi Biotech's Liu Zhenyun: When the Evolution of Life Can Be Engineered | Agentic Era
Helping Carbon-Based Life Go Further
Interview with RayzeBio: Two Funding Rounds in Six Months, How the Surging "Radiopharma" Sector Is Transforming Cancer Treatment | Gaorong Ventures
Accelerating on the "fast track" of TRT therapy.
Fu Wei, who spent ten years doing control buyouts, said they are the blue-collar workers of the investment industry.
Go with the flow.
The Truth About Weight Loss, and Innovation Opportunities | FreeS Fund Report 36
Every unique you deserves a healthier, more vibrant body.
$1 Billion! BioMap and Sanofi Partner to Develop AI Drug Discovery Models Based on Large Foundation Models | BlueRun Ventures Headlines
The First Commercial Partnership Based on Large Language Models in the Life Sciences Sector
Inside Dalton Venture's Family of Companies | Boosting Long-Term Survival Rates with a Single Injection: How This Innovative Drug Developer Is Taking on Leukemia
CAR-T cell therapy is seen as a new hope in humanity's fight against cancer.
How Does Single-Cell Sequencing Help You Understand the 40 Trillion Cells in Your Body? | 2021 FreeS Fund Annual Investor Summit
How Single-Cell Sequencing Is Revolutionizing Biomedicine
5Y News｜Vivace Therapeutics Announces Completion of Angel Round Raising Tens of Millions of RMB
Huanyi Bio announced the completion of an angel funding round of tens of millions of RMB, led by 5Y Capital.
Blue Ocean Strategy: How Early-Stage Biopharma Startups Can Break Through and Win with Big Pharma | FreeS Fund 2020 Biopharma Summit Session 3 — Registration Open
From "Me Worse" to "First in Class": How Can Biopharma Companies Compete Through Differentiation?
Beyond the "Narrow Door": A Real-World Portrait of Early-Stage Frontier Biotech Entrepreneurship in China | FreeS Fund 2020 Biotech Summit Registration Now Open
Will Today’s US Biotech Become China’s Tomorrow?
FreeS Fund Wins Multiple Awards from Zero2IPO, ChinaVenture, and Cyzone; See You Tomorrow at 9 AM in the Live Room | Frees Fund Vol. 4
Looking forward to having you join us!
Li Feng: One Chart to Decode Biotech Innovation Opportunities | Your Complete Guide to the FreeS Fund 2020 Biomedical Summit
Three Livestreams and One Offline Symposium, Decoding the Era of Biomedical Innovation
Riding the Gene Therapy Wave | Frees Fund
From Willow Bark to "God's Scalpel" — A Brief History of Drug Development
FreeS Fund Report 16: The Truth About Early-Stage Healthcare Investing and China Speed | Frees Fund
Is early-stage healthcare investment really as "high-cost, high-risk, slow-return" as they say?
